Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.
A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.
The continuous turnover of BONE MATRIX and mineral that involves first an increase in BONE RESORPTION (osteoclastic activity) and later, reactive BONE FORMATION (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium HOMEOSTASIS. An imbalance in the regulation of bone remodeling's two contrasting events, bone resorption and bone formation, results in many of the metabolic bone diseases, such as OSTEOPOROSIS.
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
A noninvasive method for assessing BODY COMPOSITION. It is based on the differential absorption of X-RAYS (or GAMMA RAYS) by different tissues such as bone, fat and other soft tissues. The source of (X-ray or gamma-ray) photon beam is generated either from radioisotopes such as GADOLINIUM 153, IODINE 125, or Americanium 241 which emit GAMMA RAYS in the appropriate range; or from an X-ray tube which produces X-RAYS in the desired range. It is primarily used for quantitating BONE MINERAL CONTENT, especially for the diagnosis of OSTEOPOROSIS, and also in measuring BONE MINERALIZATION.
Bone loss due to osteoclastic activity.
The growth and development of bones from fetus to adult. It includes two principal mechanisms of bone growth: growth in length of long bones at the epiphyseal cartilages and growth in thickness by depositing new bone (OSTEOGENESIS) with the actions of OSTEOBLASTS and OSTEOCLASTS.
Breaks in bones.
The outer shorter of the two bones of the FOREARM, lying parallel to the ULNA and partially revolving around it.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
The constricted portion of the thigh bone between the femur head and the trochanters.
The longest and largest bone of the skeleton, it is situated between the hip and the knee.
Diseases of BONES.
VERTEBRAE in the region of the lower BACK below the THORACIC VERTEBRAE and above the SACRAL VERTEBRAE.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
Tumors or cancer located in bone tissue or specific BONES.
Renewal or repair of lost bone tissue. It excludes BONY CALLUS formed after BONE FRACTURES but not yet replaced by hard bone.
A sequence of amino acids in a polypeptide or of nucleotides in DNA or RNA that is similar across multiple species. A known set of conserved sequences is represented by a CONSENSUS SEQUENCE. AMINO ACID MOTIFS are often composed of conserved sequences.
The second longest bone of the skeleton. It is located on the medial side of the lower leg, articulating with the FIBULA laterally, the TALUS distally, and the FEMUR proximally.
The spinal or vertebral column.
The projecting part on each side of the body, formed by the side of the pelvis and the top portion of the femur.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The grafting of bone from a donor site to a recipient site.
An animal or plant species in danger of extinction. Causes can include human activity, changing climate, or change in predator/prey ratios.
Calcium compounds used as food supplements or in food to supply the body with calcium. Dietary calcium is needed during growth for bone development and for maintenance of skeletal integrity later in life to prevent osteoporosis.
The bones of the free part of the upper extremity including the HUMERUS; RADIUS; and ULNA.
Extracellular substance of bone tissue consisting of COLLAGEN fibers, ground substance, and inorganic crystalline minerals and salts.
The largest of the TARSAL BONES which is situated at the lower and back part of the FOOT, forming the HEEL.
Vitamin K-dependent calcium-binding protein synthesized by OSTEOBLASTS and found primarily in BONES. Serum osteocalcin measurements provide a noninvasive specific marker of bone metabolism. The protein contains three residues of the amino acid gamma-carboxyglutamic acid (Gla), which, in the presence of CALCIUM, promotes binding to HYDROXYAPATITE and subsequent accumulation in BONE MATRIX.
Number of individuals in a population relative to space.
The measurement of the density of a material by measuring the amount of light or radiation passing through (or absorbed by) the material.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.
The process of bone formation. Histogenesis of bone including ossification.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Bones that constitute each half of the pelvic girdle in VERTEBRATES, formed by fusion of the ILIUM; ISCHIUM; and PUBIC BONE.
The process of cumulative change at the level of DNA; RNA; and PROTEINS, over successive generations.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Synthetic or natural materials for the replacement of bones or bone tissue. They include hard tissue replacement polymers, natural coral, hydroxyapatite, beta-tricalcium phosphate, and various other biomaterials. The bone substitutes as inert materials can be incorporated into surrounding tissue or gradually replaced by original tissue.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
The region of the HAND between the WRIST and the FINGERS.
The variety of all native living organisms and their various forms and interrelationships.
A functional system which includes the organisms of a natural community together with their environment. (McGraw Hill Dictionary of Scientific and Technical Terms, 4th ed)
The relationships of groups of organisms as reflected by their genetic makeup.
A potent osteoinductive protein that plays a critical role in the differentiation of osteoprogenitor cells into OSTEOBLASTS.
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
Decrease, loss, or removal of the mineral constituents of bones. Temporary loss of bone mineral content is especially associated with space flight, weightlessness, and extended immobilization. OSTEOPOROSIS is permanent, includes reduction of total bone mass, and is associated with increased rate of fractures. CALCIFICATION, PHYSIOLOGIC is the process of bone remineralizing. (From Dorland, 27th ed; Stedman, 25th ed; Nicogossian, Space Physiology and Medicine, 2d ed, pp327-33)
A large multinuclear cell associated with the BONE RESORPTION. An odontoclast, also called cementoclast, is cytomorphologically the same as an osteoclast and is involved in CEMENTUM resorption.
Bone-forming cells which secrete an EXTRACELLULAR MATRIX. HYDROXYAPATITE crystals are then deposited into the matrix to form bone.
An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.
X-RAY COMPUTERIZED TOMOGRAPHY with resolution in the micrometer range.
The growth action of bone tissue as it assimilates surgically implanted devices or prostheses to be used as either replacement parts (e.g., hip) or as anchors (e.g., endosseous dental implants).
Bone-growth regulatory factors that are members of the transforming growth factor-beta superfamily of proteins. They are synthesized as large precursor molecules which are cleaved by proteolytic enzymes. The active form can consist of a dimer of two identical proteins or a heterodimer of two related bone morphogenetic proteins.
The physical state of supporting an applied load. This often refers to the weight-bearing bones or joints that support the body's weight, especially those in the spine, hip, knee, and foot.
The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.
A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.
The arrangement of two or more amino acid or base sequences from an organism or organisms in such a way as to align areas of the sequences sharing common properties. The degree of relatedness or homology between the sequences is predicted computationally or statistically based on weights assigned to the elements aligned between the sequences. This in turn can serve as a potential indicator of the genetic relatedness between the organisms.
Resorption or wasting of the tooth-supporting bone (ALVEOLAR PROCESS) in the MAXILLA or MANDIBLE.
Elements of limited time intervals, contributing to particular results or situations.

Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. (1/1450)

OBJECTIVE: The objective of this review is to present the clinical profiles of the once-weekly and once-daily dosing formulations of alendronate and risedronate, the 2 bisphosphonates currently available in the United States for the prevention and treatment of postmenopausal osteoporosis. DATA SOURCE/STUDY SELECTION: Data were obtained from a MEDLINE literature search of all English language articles published between January 1996 and April 2004 using generic names of the bisphosphonates alendronate and risedronate. Results were refined by incorporating terms such as "osteoporosis," "bone mineral density," "fracture risk," and "adverse events." Randomized, controlled trials of once-daily and once-weekly bisphosphonate therapies were selected. Also selected for review were post hoc analyses and extension studies of the original controlled trials, including more recent data from published abstracts from scientific meetings. DATA EXTRACTION: Relevant portions of articles obtained from the literature search were used to summarize the efficacy and tolerability of the 2 therapies. CONCLUSIONS: In prospective trials, both bisphosphonates were effective in reducing vertebral and hip fractures in women with postmenopausal osteoporosis. In the only prospective trial evaluating hip fracture risk reduction as the primary end point, risedronate was effective at reducing hip fracture vs placebo. Both alendronate and risedronate are available in once-weekly formulations that have efficacy and tolerability profiles similar to the once-daily doses. Clinicians should review all available data for both agents as well as the medical history of the patient to make the most appropriate treatment choice.  (+info)

The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in juvenile systemic lupus erythematosus. (2/1450)

Glucocorticoids are widely used in the treatment of lupus patients, and adverse effects, which include osteoporosis and associated fractures, are frequent. Treatment of osteoporosis of young patients should be effective and not harmful to bone growth and remodeling. Bisphosphonates are drugs that decrease the incidence of bone fractures, but their use in juvenile patients is still controversial because of their possible side effects on the growing skeleton. However, recently published studies showed that linear growth continued normally after treatment with these drugs, and there was no excessive suppression of bone remodeling or mineralization defects. Zoledronic acid is a new intravenous bisphosphonate that has been approved by the US FDA for use with hypercalcemia of malignancies and might be an effective treatment for postmenopausal osteoporosis. The authors report a case of a young girl with systemic lupus who developed multiple vertebral collapses due to glucocorticoid therapy, and zoledronic acid was used producing significant clinical and densitometric improvement.  (+info)

Management of androgen-independent prostate cancer. (3/1450)

BACKGROUND: Although androgen withdrawal can control prostate cancer for long periods in many patients, controversy exists regarding management when the tumor becomes androgen independent. Several options are now available. METHODS: A review of the pertinent literature of the last 20 years was conducted to provide guidance in defining and managing hormone-refractory prostate cancer. RESULTS: Stage D prostate cancer can be subclassified to correlate tumor biology with disease stage. Secondary hormone manipulations may induce responses in patients after failure of initial androgen suppression, and chemotherapy with docetaxel has prolonged survival in patients with androgen-independent prostate cancer (AIPC). The weight of evidence supports the maintenance of castrate levels of testosterone in metastatic AIPC. Bisphosphonates decrease skeletal complications. CONCLUSIONS: Secondary hormone therapy, chemotherapy, and bisphosphonate therapy may provide benefits for selected patients. Correlation of disease stage with biologic characteristics of the tumor and host facilitates proper choices of interventions. Docetaxel-based chemotherapy regimens should be considered for first-line treatment of patients with progressive metastatic AIPC.  (+info)

Effect of administration of alendronate sodium and retinol on the mechanical properties of the femur in ovariectomized rats. (4/1450)

Alendronate sodium, an aminobisphosphonate with potent antiresorptive activity, is used in the treatment of postmenopausal osteoporosis. Retinol, as a component of multivitamin preparations, is frequently used especially by elderly people. There are no reports on the interaction of alendronate sodium and retinol. The aim of the present study was to investigate the effect of administration of alendronate sodium and retinol on mechanical properties of the femoral bone in bilaterally ovariectomized rats. The experiments were carried out on 3-month-old Wistar rats, divided into 7 groups: I - sham-operated control rats, II - ovariectomized control rats, III - ovariectomy + alendronate sodium 3 mg/kg po, IV - ovariectomy + retinol 700 IU/kg po, V - ovariectomy + retinol 3500 IU/kg po, VI - ovariectomy + alendronate sodium 3 mg/kg po + retinol 700 IU/kg po, VII - ovariectomy + alendronate sodium 3 mg/kg po + retinol 3500 IU/kg po. The drugs were administered to the rats daily by oral gavage for 28 days. Body mass gain, bone mass, bone mineral content and calcium content in the femur and L-4 vertebra and mechanical properties of the whole femur (extrinsic stiffness, ultimate load, breaking load, deformation caused by the ultimate load) and the neck of the femur (load at fracture), were examined. Bilateral ovariectomy induced osteopenic changes in the rat skeletal system. Alendronate sodium (3 mg/kg po) counteracted the development of osteopenia induced by ovariectomy. Retinol at both used doses unfavorably affected the examined bone parameters of ovariectomized rats. Retinol administered with alendronate sodium lessened the preventive action of alendronate on the development of osteopenic changes in the skeletal system of ovariectomized rats.  (+info)

Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. (5/1450)

Bisphosphonates, which inhibit osteoclasts, alleviate many of the devastating consequences of metastatic bone disease. However, bisphosphonates may play a role in the development of osteonecrosis of the jaws. We report our experience in the management of a patient with a history of bisphosphonate therapy who presented with osteonecrosis of the jaws following dental extraction to make others, particularly the broader dental community, aware of this potential complication. We also review the pharmacologic properties of bisphosphonates and their possible role in the pathophysiology of osteonecrosis. Until more is known about the role of bisphosphonates in the development of osteonecrosis of the jaws, we recommend that measures be taken to prevent osteonecrosis in those at risk, including, when feasible, a dental consultation before initiating bisphosphonate therapy.  (+info)

Effect of adminitration of etidronate and retinol on bone mechanical properties in ovariectomized rats. (6/1450)

The experiments were carried out on rats, divided into 7 groups: I-sham-operated control rats, II-ovariectomized (OVX) control rats, II- OVX+etidronate (10 mg/kg po), IV-OVX+retinol (700 IU/kg po), V-OVX+retinol (3,500 IU/kg po), VI-OVX+etidronate (10 mg/kg po)+retinol (700 IU/kg po), VII-OVX+etidronate (10 mg/kg po)+retinol (3 500 IU/kg po). The drugs were administered once a day for 4 weeks. Bone mass, content of mineral substances and calcium were examined in the femur, tibia and L-4 vertebra. In the femur, mechanical properties of the whole bone supported on its epiphyses (the ultimate load, the breaking load and the deformation caused by the applied load) and of the femoral neck (the load causing the fracture) were studied. Bilateral ovariectomy induced unfavorable changes in mechanical properties of rat bones, which were partially prevented by administration of etidronate. Retinol at 3,500 IU/kg po caused intensification of the osteoporotic changes, especially it worsened the mechanical properties of bones. The results of the present study do not indicate the existence of any interaction between retinol and etidronate concerning mechanical properties of bones in OVX rats.  (+info)

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. (7/1450)

OBJECTIVES: To establish the clinical effectiveness and cost-effectiveness of selective oestrogen receptor modulators, bisphosphonates and parathyroid hormone (subject to licensing) for the prevention and treatment of osteoporosis and the prevention of osteoporotic fractures in postmenopausal women. DATA SOURCES: Electronic databases. REVIEW METHODS: Studies that met the review's entry criteria were eligible for inclusion in the meta-analyses provided that they reported fracture incidence in terms of the number of patients suffering fractures. Meta-analysis was carried out using the random-effects model. A model was constructed to estimate the cost-effectiveness of osteoporosis interventions. The model calculated the number of fractures that occurred and provided the costs associated with osteoporotic fractures, and the quality-adjusted life-years (QALYs). In addition, the conditions of breast cancer and coronary heart disease (CHD) were modelled, as some interventions have been shown to affect the risk of these conditions. RESULTS: Ninety randomised controlled trials (RCTs) met the inclusion criteria. They related to the five interventions (alendronate, etidronate, risedronate, raloxifene and teriparatide) and to five comparators (calcium, calcium plus vitamin D, calcitriol, hormone replacement therapy and exercise), as well as placebo or no treatment. All five interventions have been shown to reduce the risk of vertebral fracture in women with severe osteoporosis with adequate calcium intakes. However, none of these drugs has been demonstrated, by direct comparison, to be significantly more effective than either each other or the other active interventions reviewed in this report. The intervention costs of treating all osteoporotic women, for a period of 5 years, were in the region of pound 900-1500 million for alendronate, etidronate, risedronate and raloxifene. The cost per QALY ratios fell dramatically with age. Assuming the risks of a woman with severe osteoporosis at the threshold of osteoporosis, no treatment had a cost per QALY below pound 35,000 at 50 years of age. At 60 years of age, the cost per QALY of raloxifene was pound 26,000 assuming no impact on hip fractures, and pound 31,000 assuming an adverse effect. However, these results are driven by the effect on breast cancer and the assumptions made regarding this disease state. No other intervention had a cost per QALY below pound 35,000. When analyses were conducted assuming that the fracture risk is doubled at each site, alendronate and risedronate had cost per QALY ratios below pound 30,000 at all ages. For women at the threshold of osteoporosis, without a prior fracture and aged 70 years, the cost per QALY of the three bisphosphonates ranged from pound 34,000 to pound 41,000. Raloxifene had a cost per QALY of pound 23,000, assuming no effect on hip fracture, given assumptions regarding breast cancer. At 80 years of age, the cost per QALY of alendronate and risedronate was below pound 20,000. This was true for etidronate when incorporating observational data, but the value rose to pound 69,000 when only RCT data were used. No other intervention had a cost per QALY below pound 35,000. It was assumed that doubling the risk of fracture for women without a prior fracture would give results similar to patients at the threshold of osteoporosis with a prior fracture. CONCLUSIONS: Of the five interventions, only raloxifene appeared to reduce the risk of vertebral fracture in postmenopausal women unselected for low bone mineral density (BMD). However, as the full data have not been made public, there is some uncertainty regarding this result. None of the five interventions has been shown to reduce the risk of non-vertebral fracture in women unselected for low BMD. All of the proposed interventions provided gains in QALYs compared with no treatment in women with sufficient calcium and vitamin D intakes. The size of the QALY gain for each intervention was strongly related to the age of the patient. The estimated costs varied widely for the interventions. These net costs were markedly different by age, with some interventions becoming cost-saving at higher age ranges in patients with a prior fracture. Areas for future research include: the evidence base for the efficacy of fracture prevention in the very elderly, reanalysis of raloxifene using a dedicated breast cancer and CHD model, and more trials considering the cost-effectiveness of teriparatide.  (+info)

Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. (8/1450)

BACKGROUND: Alendronate has been found to reduce the risk of fractures in postmenopausal women as demonstrated in multiple randomized controlled trials enrolling thousands of women. Yet there is a paucity of such randomized controlled trials in osteoporotic men. Our objective was to systematically review the anti-fracture efficacy of alendronate in men with low bone mass or with a history of prevalent fracture(s) and incorporate prior knowledge of alendronate efficacy in women in the analysis. METHODS: We examined randomized controlled trials in men comparing the anti-fracture efficacy of alendronate to placebo or calcium or vitamin D, or any combination of these. Studies of men with secondary causes of osteoporosis other than hypogonadism were excluded. We searched the following electronic databases (without language restrictions) for potentially relevant citations: Medline, Medline in Process (1966-May 24/2004), and Embase (1996-2004). We also contacted the manufacturer of the drug in search of other relevant trials. Two reviewers independently identified two trials (including 375 men), which met all inclusion criteria. Data were abstracted by one reviewer and checked by another. Results of the male trials were pooled using Bayesian random effects models, incorporating prior information of anti-fracture efficacy from meta-analyses of women. RESULTS: The odds ratios of incident fractures in men (with 95% credibility intervals) with alendronate (10 mg daily) were: vertebral fractures, 0.44 (0.23, 0.83) and non-vertebral fractures, 0.60 (0.29, 1.44). CONCLUSION: In conclusion, alendronate decreases the risk of vertebral fractures in men at risk. There is currently insufficient evidence of a statistically significant reduction of non-vertebral fractures, but the paucity of trials in men limit the statistical power to detect such an effect.  (+info)

While a kidney transplant can restore healthy kidney function, recipients remain at increased risk of fractures, heart disease, diabetes and some cancers. The VITALE study shows that, compared with currently recommended doses, high doses of oral vitamin D (cholecalciferol) lower the risk of fractures, but have no effect on the risks of heart disease, diabetes or cancer after a kidney transplant.
New study reveals that oral bisphosphonate osteoporosis drugs including Actonel, Boniva, and Fosamax, could be associated with esophageal cancer.
Custom Building Products offer quality surface preparation solutions for any tile or stone installation. Learn about Custom 9240.
A new UK study that followed a large number of people found that those who took 10 or more prescriptions for oral bisphosphonates, a group of drugs commonly used to treat the bone disease, were at higher risk of developing esophageal cancer.
This is a two-site, three-arm, open-label, pilot randomized controlled trial of bone anti-resorptive therapy during ART initiation in HIV-infected adults. Thirty (30) treatment-naïve HIV-infected adults initiating eligible first-line ART regimens will be randomized in a 1:1:1 fashion to one of the following three arms:. ...
A very seldom mentioned effect of bisphosphonates (drugs such as Fosamax, Actonel, and Boniva) is that these drugs block very important metabolic pathways. Even if you never took bisphosphonates, you
Persistence rate over 12 months of teriparatide treatment was 34.9% in Japan. Approximately one-third of patients had no subsequent treatment immediately after teriparatide. Monitoring persistence and considering subsequent drugs for osteoporosis are necessary for teriparatide treatment.
Results 33 patients who were started on teriparatide treatment between 2011-2015 were identified (29 female and 4 male). Mean age was 76.2 (range 63-92). All had pre-treatment DXA, and 32 (97%) were compliant with recommendations for initiation of teriparatide treatment with respect to DXA (one patient borderline). All 33 patients had a pre-treatment bone profile within acceptable limits before start of treatment (adjusted Calcium, Serum Parathyroid Hormone, Vitamin D level, e-gfr). 28 (84.8%) patients tried one agent before initiation of Teriparatide treatment and 5 (15.2%) patients tried 2 agents. 24 (72.7%) patients completed the full course of recommended treatment. 11 out of 24 patients who completed Teriparatide treatment have had post-treatment DXA. 3 out of 24 patients who completed Teriparatide treatment had a fragility fracture after treatment. ...
There are no data on the use of denosumab in steroid induced osteoporosis. Postmenopausal women with chronic use of Glucocorticoid (GCs) are at high-risk of osteoporotic fractures. Despite bisphosphonate treatment, a certain proportion of high-risk patients using chronic GCs either do not achieve a satisfactory gain in bone mineral density (BMD) or develop new fragility fractures. Thus, more potent osteoporosis treatment is necessary for this subgroup of patients. This prompts the current study which aims to examine the efficacy of denosumab in current users of oral bisphosphonates for Glucocorticoid-induced Osteoporosis (GIOP ...
The options available for effective osteoporosis treatment continue to grow. Because of the large number of treatment options, many clinicians, particularly in primary care, are uncertain about when to start therapy, which drug to use, and when to stop. The issue of when to stop antifracture therapy is now front and center as evidence accumulates that the antifracture benefits of some treatments persist after discontinuation and as patients increasingly voice concerns about possible rare but serious problems linked to osteoporosis treatment, such as atypical femoral fractures, osteonecrosis of the jaw, arrhythmias, and cancer. The decision about when to stop or change osteoporosis treatment is particularly complex and should be influenced by the expected benefits and harms of continued use and at least some information about what to expect after therapy is stopped (also known as resolution-of-effect). A prolonged skeletal resolution-of-effect, characteristic of at least some bisphosphonates, might be
A prospective, randomized and double blind once-monthly oral Ibandronate and Risedronate in post-menopausal osteoporosis leprosy patients
This page provides useful content and local businesses that can help with your search for Osteoporosis Treatments. You will find helpful, informative articles about Osteoporosis Treatments, including 5 Tips for Preventing Osteoporosis. You will also find local businesses that provide the products or services that you are looking for. Please scroll down to find the local resources in Gainesville, GA that will answer all of your questions about Osteoporosis Treatments.
This page provides useful content and local businesses that can help with your search for Osteoporosis Treatment. You will find helpful, informative articles about Osteoporosis Treatment, including Osteoporosis. You will also find local businesses that provide the products or services that you are looking for. Please scroll down to find the local resources in Chaska, MN that will answer all of your questions about Osteoporosis Treatment.
This page provides useful content and local businesses that can help with your search for Osteoporosis Treatment. You will find helpful, informative articles about Osteoporosis Treatment, including Osteoporosis. You will also find local businesses that provide the products or services that you are looking for. Please scroll down to find the local resources in Buckhannon, WV that will answer all of your questions about Osteoporosis Treatment.
Doctor answers on Symptoms, Diagnosis, Treatment, and More: Dr. Kimm on once a year osteoporosis medication: Hello~ ZOSTAVAX +65yo + MTX ?? ANSWER: YES ABSOLUTELY DEFINITELY YESTERDAY ! THANKS for topic: Once A Year Osteoporosis Medication
Bisphosphonates are common first line medications used for the management of benign bone disease. One of the most devastating complications associated with bisphosphonate use is osteonecrosis of the jaws which may be related to duration of exposure and hence cumulative dose, dental interventions, medical co-morbidities or in some circumstances with no identifiable aggravating factor. While jaw osteonecrosis is a devastating outcome which is currently difficult to manage, various forms of delayed dental healing may be a less dramatic and, therefore, poorly-recognised complications of bisphosphonate use for the treatment of osteoporosis. It is hypothesised that long-term (more than 1 years duration) bisphosphonate use for the treatment of post-menopausal osteoporosis or other benign bone disease is associated with impaired dental healing. A case-control study has been chosen to test the hypothesis as the outcome event rate is likely to be very low. A total of 54 cases will be recruited into the study
Osteoporosis is a disease that affects the bones. As the bones start loosing their usual density they become weaker & are more likely to break. Studies have shown that every one in two women & every one in four men above the age of 50 tend to break bones due to osteoporosis. It can cause serious complications & appropriate measures must be taken to avoid extreme consequences.. There is no exact cure for osteoporosis. The idea of the osteoporosis treatment process is to strengthen the bones in order to protect them. The treatment primarily consists of a combination of drugs and suitable lifestyle changes that help in minimising the rate of bone resorption.. Preventive measures include a modification in the general lifestyle factors, doing more muscle-strengthening exercises and ensuring adequate intake of calcium and vitamin D.The medications used for osteoporosis treatment are anti-resorptive agents. Osteoporosis occurs when the rate of resorption in the bones overtakes the rate of bone ...
Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedules. Such regimens require high potency agents, which can be given at low effective doses and that also have good tolerability. Ibandronate is a potent, nitrogen-containing bisphosphonate with proven efficacy when given intermittently to estrogen-depleted beagle dogs, rats and cynomolgus monkeys. Clinically, a pivotal prospective study has established that oral ibandronate has significant vertebral fracture efficacy in PMO, whether given daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months; extended between-dose interval|2 months). Both oral regimens were well tolerated, which is noteworthy as patients with a history
We did not find any significant correlation between BMD variation and CTX, P1NP, PTH, calcium or 25OHD levels during the study. There was no statistically significant difference between the group with or without clinically significant BMD loss and baseline CTX and P1NP levels, and no difference was observed between CTX or P1NP levels during the follow-up period and prevalence of BMD loss, either.. DISCUSSION. Bisphosphonates increase BMD by slowing bone turno-ver and allowing secondary mineralization to progress, which in turn leads to increased bone mineral content (11). By inhibiting osteoclast action (and therefore bone resorption), bisphosphonates, such as alendronate, act reducing BTM levels and increasing BMD. Although changes in BMD and BTM cannot entirely explain observed fracture risk reduction with alendronate therapy (13,14), these are the most important predictors of fracture risk in clinical practice, and the most easily measurable surrogates for treatment-related efficacy in ...
In QResearch 4.6% of cases and 4.5% of controls had one or more prescriptions for bisphosphonates, as did 4.8% and 4.6%, respectively, in CPRD. About two thirds of patients with a diagnosis of osteoporosis had been prescribed bisphosphonates (64% of cases and 65% of controls in QResearch and 61% and 60%, respectively, in CPRD) and 2% of cases and controls in both databases had prescriptions for bisphosphonates without records of osteoporosis. Bisphosphonate users were more likely to be women and to have a lower BMI. Upper gastrointestinal problems were slightly more common (QResearch: cases 25% in users v 22% in non-users, controls 25% v 20%; CPRD: cases 35% v 29%, controls 33% v 27%) and use of acid lowering drugs was much more common in bisphosphonate users (QResearch: cases 62% in users v 37% in non-users, controls 61% v 32; CPRD: cases 65% v 39%, controls 63% v35%). Among bisphosphonate users, the proportion of patients with rheumatoid arthritis was more than five times higher than in ...
Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis Ege Can Serefoglu1, Zafer Tandogdu21Kiziltepe Hospital, Department of Urology, Mardin, Turkey; 2Taksim Teaching Hospital, Department of Urology, Istanbul, TurkeyAbstract: Glucocorticoids are essential in treating many disorders and they are widely used in spite of their negative impact on the skeletal system. As bisphosphonates reduce bone resorption through their action on osteoclasts, they play an important role in management of glucocorticoid-induced osteoporosis. Unlike other bisphosphonates, zoledronic acid is given by intravenous infusion and it has a potential advantage of increasing the compliance and adherence of patients when it is given 5 mg once a year. However, this treatment modality seems to be associated with more adverse events than oral administrations, and further studies with longer follow-up periods must be conducted to determine the safety and cost-effectiveness of long-term treatment
Reclast zoledronic acid - How long is fasting required before reclast (zoledronic acid) is taken? Good news for you! Hi. You DO NOT HAVE TO FAST before, during, or after Reclast (zoledronic acid) being given! Reclast (zoledronic acid) is given intravenously, bypassing the GI tract entirely (unlike the oral bisphosphonates, which require fasting). Bon appetite!
This phase II study will evaluate the efficacy of radiotherapy in combination with zoledronic acid on pain relief and the safety of radiotherapy in bone
Pharmacologic Profile of Risedronate Like all bisphosphonates, risedronate selectively adsorbs to active bone remodeling sites, where it acts to inhibit osteoclast-mediated bone resorption. Risedronate reduces the risk of fracture by preventing bone loss.10 This action results in increased BMD at fracture-prone skeletal sites, notably the lumbar spine and hip, in postmenopausal women with osteopenia11 or osteoporosis.12,13 It has the same effect in patients initiating14 or receiving15 high-dose, longterm ( 6 months) glucocorticoid therapy (prednisone 7.5 mg/d or equivalent). Pharmacokinetic Properties The pharmacokinetic characteristics of risedronate are summarized in Table 3.8,16-19 Risedronate is absorbed rapidly after oral administration and exhibits linear pharmacokinetics over the oral single-dose range of 5 mg to 30 mg.20 The extent of risedronate absorption is comparable when the dose is taken 30 minutes before breakfast or 2 hours after the evening meal, which may permit dosing ...
MAYWOOD, Ill. - Taking time off from certain osteoporosis drugs may be beneficial to bone health, according to a study conducted at Loyola University Health System. Researchers found that bone density remained stable for three years in patients who took a drug holiday from bisphosphonates, a popular class of osteoporosis drugs that can cause fractures in the thigh bones and tissue decay in the jaw bone.. These drugs are potentially harmful when taken for long durations, yet little has been known until now about the length of time osteoporosis patients should go without treatment for this debilitating condition, said Pauline Camacho, MD, study investigator and director of the Loyola University Osteoporosis and Metabolic Bone Disease Center. Our study demonstrated that bones can remain stable for a number of years after these drugs are discontinued.. Doctors recommend that patients take drug holidays from bisphosphonates after four to five years. These drugs continue to stabilize bones and ...
Osteoporosis medication can be a critical way to prevent bone loss and strengthen your bones. Learn more about osteoporosis treatments in this video.
A trend to watch in the postmenopausal osteoporosis drugs market is the emergence of novel agents. There have been encouraging developments in the postmenopausal osteoporosis drug
Fosamax low vitamin d, alendronate sodium trihydrate manufacturers, ic alendronate sodium 70 mg tab, alendronate 70 mg price, alendronate sodium 70 mg tab, fosamax 70 mg once weekly, alendronate sodium trihydrate structure
Longer intervals between zoledronic acid doses for patients with bone metastases did not result in an increased risk of skeletal-related events (SREs).
Dr. Kremer and co-lead author, Dr. Nancy Mayo, worked with colleagues to evaluate data from more than 21,000 women diagnosed with breast cancer. The relationship between use of oral bisphosphonates and development of bone metastases after diagnosis with breast cancer was evaluated in two groups of women: those with early stage, localized, cancer and those whose cancer had spread to lymph nodes. Their findings showed that women with early stage breast cancer who had taken oral bisphosphonates, either before or after diagnosis of their cancer, had a reduced risk of bone metastasis. In addition, their study showed that women with later stage cancer, who took oral bisphosphonates post-diagnosis, also had a significantly reduced risk of bone metastasis. The researchers also established a dose-response relationship with oral bisphophonate use in women with local disease: longer time spent on bisphophonate medication resulted in a greater reduction of bone metastases. Our study is novel in that it ...
The herbs used in TCM are known for their many therapeutic properties. To investigate their potential in preventing osteoporotic fractures, Taiwanese researchers conducted a nationwide, population-based cohort study. They identified osteoporosis cases and selected a comparison group that was frequency-matched according to sex, age (per five years), diagnosis year of osteoporosis, and index year. They also estimated the difference between the two groups in terms of the development of fracture using the Kaplan-Meier method and the log-rank test.. After the insertion of age, gender, urbanization level, and comorbidities into the Coxs proportional hazard model, the researchers found that the patients who used TCM had a lower hazard ratio of fracture compared to those who did not use TCM. Based on the Kaplan-Meier curves, they also reported that osteoporosis patients who used TCM had a lower incidence of fracture than those who did not. In addition, the researchers observed that patients who used ...
That two word phrase - osteoporosis medications - its so commonplace that most of us dont think much about it. Medications sounds normal, doesnt it? And of course, big pharma
It is a double blind randomized study aiming at estimating the efficiency of oral bisphosphonates on the decrease of osteoporosis by comparing the...
en] Bone Density/drug effects ; Bone Density Conservation Agents/therapeutic use ; Clinical Trials as Topic ; Drug Approval/methods ; Female ; Glucocorticoids/adverse effects ; Humans ; Male ; Osteoporosis/chemically induced/drug therapy/prevention & control ; Research Design ; Sex ...
The Bisphosphonates market is mainly driven by the incidence and prevalence rate of bone diseases. The expansion in geriatric population is the major driver for the bisphosphonates market. Ageing people start losing bone density and may suffer from fractures therefore bisphosphonate treatment becomes necessary for such patients. According to the U.S. Department of Health and Human Services, 2013 survey, nearly 14.1% of the U.S. population was aged above 65 years and is increasing rapidly. Another significant factor favorable for the growth of bisphosphonates market is the escalation in the number of women in the post-menopausal stage, who suffer from the weakening bones. The total number of women attaining menopause is estimated to cross 1 bn. by 2025, according to the International Menopause Society the number of menopausal women is higher in the developing. Incidence rate of cancers like myeloma which cause loss of bone density. Bisphosphonates are also used for therapy in the patients ...
With the launch of the first prescription osteoporosis medication 15 years ago, millions of Americans with the bone-thinning disease began taking the drugs and never looked back.. But now many bone-health doctors are looking back and becoming increasingly uneasy.. In the last few years, evidence has emerged that long-term use of osteoporosis drugs - particularly the oldest class of drugs, the bisphosphonates - may do more harm than good.. ...
03 June 2012 Toronto - New research presented today draws a significant link between the development of osteoporosis, osteoporosis treatment and a reduced risk of breast cancer recurrence.. The study was one of a total of 20 abstracts to be presented by the NCIC Clinical Trials Group (CTG) at the American Society of Clinical Oncology (ASCO) meeting in Chicago. The meeting is considered to be the premier scientific event for oncology professionals. The presentations focus on new ways to treat a variety of cancers including breast, colorectal, lung and prostate.. Todays ASCO presentation is an exploratory study within a completed large clinical trial, which involved more than 7,000 postmenopausal breast cancer patients. The objective of the original trial was to compare the use of two aromatase inhibitors (AIs) - exemestane and anastrozole - as adjuvant therapy to determine which was more effective at preventing recurrence of the disease. Adjuvant therapy is used after initial treatment for ...
03 June 2012 Toronto - New research presented today draws a significant link between the development of osteoporosis, osteoporosis treatment and a reduced risk of breast cancer recurrence.. The study was one of a total of 20 abstracts to be presented by the NCIC Clinical Trials Group (CTG) at the American Society of Clinical Oncology (ASCO) meeting in Chicago. The meeting is considered to be the premier scientific event for oncology professionals. The presentations focus on new ways to treat a variety of cancers including breast, colorectal, lung and prostate.. Todays ASCO presentation is an exploratory study within a completed large clinical trial, which involved more than 7,000 postmenopausal breast cancer patients. The objective of the original trial was to compare the use of two aromatase inhibitors (AIs) - exemestane and anastrozole - as adjuvant therapy to determine which was more effective at preventing recurrence of the disease. Adjuvant therapy is used after initial treatment for ...
For osteoporosis patients unable to exercise, help may be on the way. Thats because scientists have discovered precisely how mechanical stress, such as exercise, promotes new bone growth. This opens the door to entirely new therapies that can trick bones into thinking they are getting a workout.
Although oral bisphosphonates (BPs) are highly effective in preventing fractures, some patients will fracture while on treatment. We identified predictors of such fractures in a population-based cohort of incident users of oral BPs. We screened the Sistema dInformació per al Desenvolupament de lInvestigació en Atenció Primària (SIDIAP) database to identify new users of oral BPs in 2006-2007. SIDIAP includes pharmacy invoice data and primary care electronic medical records for a representative 5 million people in Catalonia (Spain). Exclusion criteria were the following: Paget disease; |40 years of age; and any antiosteoporosis treatment in the previous year. A priori defined risk factors included age, gender, body mass index, vitamin D deficiency, smoking, alcohol drinking, preexisting comorbidities, and medications. Fractures were considered if they appeared at least 6 months after treatment initiation. Fractures while on treatment were defined as those occurring among participants persisting
Zoledronic Acid (ZA) is a potent nitrogen-containing bisphosphonates (NBP) has been extensively used to limit bone turnover in a various diseases including tumors. Recently, clinical trails of Zoledronic Acid demonstrated direct anti-cancer effects as well as the known skeletal-related events. We investigated the effect of 4 NBPs on human tumor cells proliferation and found ZA is most potent for GBM cell, breast cell and GBM patients stem-cell-like cells. ZA also effectively inhibited GBM tumor growth in mouse model. ZA stimulated strong autophagy but not apoptotic signals in all tested cells. One intermediate product of cholesterols synthesis pathway--geranylgeranyl diphosphate (GGPP) rescued cell from the cytotoxicity of ZA. Knock-down RABGGTA, which encoded a subunit of the Rab geranylgeranyltransferase proteins, induced a similar effect as Zoledronic Acid in cancer cell lines. These data suggested great potential for Zoledronic Acid against human cancer.. Note: This abstract was not ...
osteoporosis treatment - Osteoporosis diagnosis usually comes after a fracture or fall, when the weakened bones have caused the damage
Most treatments only slow bone loss. Instead, get the ONLY natural osteoporosis treatment guaranteed to INCREASE bone density. Discover more now!
Zoledronic acid (sometimes called zoledronate) is a bisphosphonate (bis FOS fo nayt) medicine that alters bone formation and breakdown in the body. This can slow bone loss and may help prevent bone fractures. Reclast and Zometa are two different brands of zoledronic acid. Reclast is used to treat osteoporosis...
Once youve lost bone density, you cant regain it. However, osteoporosis treatment includes lifestyle changes and medications to help slow its progress.
The worldwide osteoporosis drugs market is predicted to witness a notable growth due to the growing occurrence of osteoporosis along with growing old age population during the estimated period. Availability of technically advanced treatment alternatives combined with growing levels of patient awareness, occurrences of chronic ailments and lifestyle related ailments are further predicted to promote the growth and expansion of the global osteoporosis drugs market.. Browse Full Report Visit - http://www.acutemarketreports.com/report/osteoporosis-drug-market-report. Osteoporosis is a chronic ailment that is featured by reduction in bone mass and bone tissues resulting in bone cracks & fractures. It is also considered as a life threatening ailment owing to serious damage and related pain with it. Few of the factors causing osteoporosis are genetic factors, old age, calcium deficiency, vitamin D deficiency, wrong dietary habits, sedentary/inactive lifestyle, and smoking, low body mass, excessive ...
Metabolic Pharmaceuticals has announced a trans-Tasman licensing deal and research collaboration to develop a new osteoporosis treatment.
Medigo lists trusted healthcare providers offering Osteoporosis Treatment. Compare clinics, hospitals, prices, and reviews, and get a free quote.
Oral regimens for the treatment of osteoporosis, mostly oral bisphosphonates, expose only low efficacy due to their relatively high rate of side-effects and adverse events, with very low persistence rates [2] of about 30% and 9% after 1 and 5 years, respectively [3]. The introduction of intravenous bisphosphonates improved persistence and rendered possible for the first time reliable study outcomes on the efficacy and safety of these drugs, particularly of zoledronic acid, as described in the paper by Black and colleagues [1]. Nevertheless, according to a former study, approximately one-third of patients treated with zoledronic acid suffer from post-infusion symptoms such as pyrexia, influenza-like symptoms, myalgia, headache and arthralgia after the first infusion, and the number of patients with arrhythmia or serious atrial fibrillation is significantly higher in the zoledronic acid group than in the placebo group [4]. Such side-effects and adverse events might be one reason for the small ...
Extracted from text ... SA Pharmaceutical Journal - April 2006 40 DRUG INFO Protos(r) - The first of a new class for osteoporosis: dual action bone agent Approved indication Protos(r) contains strontium ranelate and is indicated for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and peripheral fractures, including the hip. Mode of action Strontium ranelate has a unique pharmacological profile characterised by an inhibition of bone resorption and a simultaneous stimulation of bone formation. It targets the bone remodelling process by stimulating osteoblast-mediated bone formation and by inhibiting osteoclast-mediated bone resorption. The dual mode of action of strontium ranelate may ..
Results Number of the patients were 53 (male: 4 cases, female: 49 cases), and their characteristics at the beginning of denosumab treatment were as below; age: 64.19±12.0 years old, dose of prednisolon: 10.59±9.97mg/day, BMD of lumber spine: 0.768±0.112g/cm3, T-score of lumber spine: -2.28±1.01, BMD of femoral neck: 0.540±0.085g/cm3, T-score of femoral neck: -2.28±0.76. After 2-years denosumab treatment, T-scores of lumber spine (0.54±0.39 gain) and femoral neck (0.13±0.26 gain) were significantly increased from baseline (Figure; mean ± SEM. *:p,0.05). In addition, the serum markers of bone metabolism, both absorption and formation, were significantly suppressed with denosumab. ...
Bisphosphonates Break Down Bones. A second unrelated study was conducted by the Hospital for Special Surgery in New York City. This team looked at the bone makeup of 21 postmenopausal women who were treated for fractures.. Twelve of the women had been taking osteoporosis drugs for at least three years. The other nine had never taken osteoporosis drugs.. The research team took samples from each patients femur. And analyzed the bones themselves. They used cutting-edge equipment to look at the actual structure of the bone and its properties.. And they discovered big differences between the two groups. They found that the bone tissue was breaking down in the drug group. It was as if the thigh bones were literally crumbling.. When they looked back at the records they found something else significant. All the women in the non-drug group had suffered fracture through injury and accident. But the women in the drug group had suffered the fractures through simple daily living.. Debra Pate is a member of ...
... spermatogenesis-blocking agents MeSH D27.505.696.207 - astringents MeSH D27.505.696.242 - bone density conservation agents MeSH ... bone cements MeSH D27.720.102.187 - cariogenic agents MeSH D27.720.102.223 - cariostatic agents MeSH D27.720.102.339 - dental ... antiviral agents MeSH D27.505.954.122.388.077 - anti-retroviral agents MeSH D27.505.954.122.388.077.088 - anti-hiv agents MeSH ... tocolytic agents MeSH D27.505.954.016 - anti-allergic agents MeSH D27.505.954.122 - anti-infective agents MeSH D27.505.954.122. ...
The cleaning process was used in the conservation of the USS Monitor and the Philadelphia Museum of Art. Due to the blast media ... Dry ice replaces traditional cleaning methods that rely on manual scrubbing and the use of chemical cleaning agents. Dry ice ... How CO2 Blasting Works "High Density CO2". Retrieved 18 July 2018. Moore, David E., US patents#4,617,064 and #4,744,181 Jet, ... Method of removing meat from bone, 21 January 1960, retrieved 24 September 2018 Method for the removal of unwanted portions of ...
It is due to the scanner being unable to differentiate between a small amount of high-density material (e.g., bone) and a ... The old radiocontrast agents caused anaphylaxis in 1% of cases while the newer, low-osmolar agents cause reactions in 0.01-0.04 ... Payne, Emma Marie (2012). "Imaging Techniques in Conservation" (PDF). Journal of Conservation and Museum Studies. 10 (2): 17-29 ... The contrast agent may induce contrast-induced nephropathy. This occurs in 2 to 7% of people who receive these agents, with ...
At night when he sets up camp, Thor eats the meat of the goats, but takes care that all bones remain whole. Then he wraps the ... They have been described as "eating machines" and "biological control agents". There has been a resurgence of this in North ... This form of using goats to clear land is sometimes known as conservation grazing. Since then, numerous public and private ... density, uniformity, fineness, and general body confirmation. Disqualifications include: a deformed mouth, broken down pasterns ...
They have been described as "eating machines" and "biological control agents".[57][58] There has been a resurgence of this in ... When a farmer's son who is invited to share the meal breaks one of the goats' leg bones to suck the marrow, the animal's leg ... This form of using goats to clear land is sometimes known as conservation grazing. Since then, numerous public and private ... density, uniformity, fineness, and general body confirmation. Disqualifications include: a deformed mouth, broken down pasterns ...
... www.canada.ca/en/conservation-institute/services/agents-deterioration.html) (DOI museum /emergency-management plan https://www. ... Any objects close to the ceiling are covered in low-density, polyethylene plastic sheeting to prevent any water damage from ... Increased use of vitrines and plexi-glass covers for objects made of organic materials (leather, rawhide, straw, bone, shell, ... "Preventive Conservation". International Council of Museums-Committee for Conservation. Retrieved April 3, 2014. Buck, Rebecca; ...
Ho-Pham, Lan T; Nguyen, Nguyen D; Nguyen, Tuan V (October 2009). "Effect of vegetarian diets on bone mineral density: a ... What's in question isn't the value of the parasite or predator's ecological role, but whether intelligent moral agents can ... In 2010, Paul Watson of the Sea Shepherd Conservation Society called pigs and chicken "major aquatic predators", because ... enabling mineralization of bone, and bone growth. Without it bones can become thin and brittle; together with calcium it offers ...
gypsum plasters, leavened with polystyrene beads, as well as chemical expansion agents to decrease the density of the finished ... Practical Building Conservation. Mortars, Renders & Plasters. Farnham / Burlington: Ashgate. p. 87.. *^ Franz Wirsching " ... It keeps the fractured bone straight. This use is based on the fact that when plaster of Paris is mixed with a proper quantity ... European Illustrated Glossary Of Conservation Terms For Wall Paintings And Architectural Surfaces. English Definitions with ...
Fewer species were found along the first road with density estimates being almost 80% lower than at the second site that which ... Since then, the term has gained broader usage in conservation biology as a global phenomenon. It is estimated that more than 50 ... The results suggested that higher levels of fragmentation within the fish-bone pattern led to the loss of species and decreased ... If seed dispersal agents are targeted by hunters, the effectiveness and amount of dispersal for those plant species will be ...
... bone density, and the proliferation of endometrial cells. miR-181 could acquire a resistance to tamoxifen, the drug is ... Tamoxifen acts as an anti-estrogen (inhibitor) in breast tissue, but as an estrogen (stimulating agent) in cholesterol ... "Conservation of small RNA pathways in platypus". Genome Research. 18 (6): 995-1004. doi:10.1101/gr.073056.107. PMC 2413167 . ... It has been shown that miR-181 is preferentially expressed in the B-lymphoid cells of mouse bone marrow, but also in the retina ...
Migratory Bird Conservation Commission (U.S.) MBCS - (i) Multi-Byte Character Set MBE (p) Member of the Order of the British ... Meat and Bone Meal MbS - (i) Mohammad bin Salman (current crown prince of Saudi Arabia) MBSE - (i) Model-based systems ... Multi-Agent Computing Environment MACHO - (p) MAssive Compact Halo Object MAD (a) Magnetic Anomaly Detector (s) Moroccan dirham ... Main distribution frame Medium-density fiberboard MDG (s) Madagascar (ISO 3166 trigram) (i) UN Millennium Development Goal MDL ...
Animal glue is an adhesive that contains various animal parts such as bone, skin, or fish and is widely used. It is a soft ... Different grades of plasters are available and vary based on their particle size, setting time, density, expansion, and color. ... as is difficulty in manipulating the substance as a workable agent. The most suitable solvent for B-72 is acetone. Unlike ... Care and conservation of ceramic and glass by The Institute of Conservation Conservation of ceramics at the Victoria & Albert ...
The reducing agent is commonly a fossil fuel source of carbon, such as coke-or, in earlier times, charcoal. The oxygen in the ... It is too soft to use for structural elements or weapons, though its high density relative to other metals makes it ideal for ... Metals were hard enough to make weapons that were heavier, stronger, and more resistant to impact damage than wood, bone, or ... Environmental Conservation. 1 (2): 123-13 2. doi:10.1017/S0376892900004240. ISSN 1469-4387. Likens, Gene E.; Wright, Richard F ...
Some other bone matrix proteins such as osteopontin and bone sialoprotein use both the first and the second. Direct activation ... Its density of 1.55 g/cm3 is the lowest in its group.[5] Calcium is harder than lead but can be cut with a knife with effort. ... It is also used as a reducing agent in the production of chromium, zirconium, thorium, and uranium. It can also be used to ... so the decay is forbidden by the conservation of angular momentum. While two excited states of 48Sc are available for decay as ...
... and years for bone.[21] Lead in the bones, teeth, hair, and nails is bound tightly and not available to other tissues, and is ... A chelating agent is a molecule with at least two negatively charged groups that allow it to form complexes with metal ions ... conservation programs exist which routinely capture condors, check their blood lead levels, and treat cases of poisoning.[242] ... Its density, workability, and corrosion resistance were among the metal's attractions.[142] ...
Sheep bones along with a handful of pig, rabbit and cattle bones were also found from this period. Fish bones dominate the ... Ltd.; 1911 Norddeutscher Lloyd, P.P. Lohmann and Co., General Agents; 1911 Gibbs Bright and Co.) made requests to the Collector ... Robertson and Hindmarsh (1998). Conservation Plan of 75 + 75a George Street, The Rocks. Sands, John. Sands Sydney and Suburban ... together with Samson's Cottage wall remains illustrates the development of Sydney at ever higher densities. In this regard, its ...
Cell parameters have been calculated for its octahydrate; they lead to conclusion that the density of Pm2(SO4)3·8 H2O is 2.86 g ... It is not known what human organs are affected by interaction with promethium; a possible candidate is the bone tissues. Sealed ... treating chemical compounds containing Pm3+ ions with strong oxidizing or reducing agents showed that the ion is not easily ... are forbidden by energy conservation. In particular, careful measurements of atomic masses show that the mass difference 150Nd- ...
Decellularized allografts have been critical in bone grafts that function in bone reconstruction and replacing of deformed ... Proper conservation of ECM fibers, growth factors, and other proteins is imperative to the progenitor cells differentiating ... EDTA is a chelating agent that binds calcium, which is a necessary component for proteins to interact with one another. By ... The success of decellularization varies based on the components and density of the applied tissue and its origin. The ...
The half-life of lead in bone has been estimated as years to decades, and bone can introduce lead into the bloodstream long ... A chelating agent is a molecule with at least two negatively charged groups that allow it to form complexes with metal ions ... Its density, workability, and corrosion resistance were among the metal's attractions. In the 2nd century BC the Greek botanist ... Also, conservation programs exist which routinely capture condors, check their blood lead levels, and treat cases of poisoning ...
It is due to the scanner being unable to differentiate between a small amount of high-density material (e.g., bone) and a ... The contrast agent may induce contrast-induced nephropathy.[15] This occurs in 2 to 7% of people who receive these agents, with ... Journal of Conservation and Museum Studies. 10 (2): 17-29. doi:10.5334/jcms.1021201.. ... The old radiocontrast agents caused anaphylaxis in 1% of cases while the newer, lower-osmolar agents cause reactions in 0.01- ...
Affected high-density populations suffered up to 100% mortality in 12-18 months. Between 1996 and 2015, DFTD wiped out 95% of ... Oocyte banking may be useful in the conservation effort for Tasmanian devils, as the survival rate of cryopreserved oocytes is ... The theory that cancer cells themselves could be an infective agent (the Allograft Theory) was first offered in 2006 by Pearse ... Tumours are locally aggressive, destroying the underlying bone of the jaw which interferes with feeding. Tumours may also cover ...
Otoliths - calcareous deposits or bones found in chambers at the base of the skull in fish. Sectioned, these bones often show ... the International Union for the Conservation of Nature and Natural Resources is the world's main authority on the conservation ... Species density - the number of species in a sampled area. Species group - a group of similar species. Similar species are ... Alginate production - a gel substance extracted from brown algae and used industrially as a thickening agent for food and paint ...
Byssal threads, used to anchor mussels to substrates, are now recognized as superior bonding agents. A number of studies have ... Williams, James D.; Jr, Melvin L. Warren; Cummings, Kevin S.; Harris, John L.; Neves, Richard J. (1993-09-01). "Conservation ... where the most common method is to attach mussels to ropes which are hung from a rope back-bone supported by large plastic ... from areas where they have settled naturally to areas where they can be placed in lower densities to increase growth rates, ...
... emphasizing the impact of bone-density tests and explaining the process using Ann Richard's own bone test as an example; ... but also lawmakers allowing her to be an agent of change in Texas government. Richards was defeated in the 1994 Republican ... the National Wildlife Federation Conservation Achievement Award, the Orden del Aguila Azteca (Order of the Aztec Eagle) ... She changed her diet and lifestyle, and then her bone density stabilized. She spoke frequently about this experience, teaching ...
The high amount of calcium (Z = 20) in bones, together with their high density, is what makes them show up so clearly on ... A head CT scan (1.5mSv, 64mGy) that is performed once with and once without contrast agent, would be equivalent to 40 years of ... The transferred energy can be directly obtained from the scattering angle from the conservation of energy and momentum. ... Bones contain a high concentration of calcium, which, due to its relatively high atomic number, absorbs x-rays efficiently. ...
Bone disease. As calcium is required for bone development, many bone diseases can be traced to the organic matrix or the ... Its density of 1.55 g/cm3 is the lowest in its group.[7] Calcium is harder than lead but can be cut with a knife with effort. ... It is also used as a reducing agent in the production of chromium, zirconium, thorium, and uranium. It can also be used to ... so the decay is forbidden by the conservation of angular momentum. While two excited states of 48Sc are available for decay as ...
Alpert P, Bone E, Holzapfel C (January 2000). "Invasiveness, invasibility and the role of environmental stress in the spread of ... Decoupling of the relationship between some biocontrol agents and their targets can support invasions. On the other hand the ... There has been criticism regarding this method, for example when species in conservation areas have been affected or even ... The impact on native species can be altered through population densities of invasive species. Competition interactions and ...
The identity of the bacterial agent remains unknown. Vitamin E, fluoride, and iodide protect against bone loss associated with ... Population densities are usually below 10 per ha (four per acre) and home ranges vary from 0.23 to 0.37 ha (0.57 to 0.91 acres ... The 2016 IUCN Red List assesses the conservation status of the marsh rice rat as "Least Concern", because it is a common, ... The nasal and premaxillary bones extend back beyond the point where the lacrimal, frontal, and maxillary bones meet. In P. o. ...
The diagnosis of brucellosis relies on: Demonstration of the agent: blood cultures in tryptose broth, bone marrow cultures: The ... Since concentrating animals around food plots accelerates spread of the disease, management strategies to reduce herd density ... Conservation Biology. 8 (3): 645-653. doi:10.1046/j.1523-1739.1994.08030645.x. JSTOR 2386505. Archived from the original (PDF) ... agent US) Bovine brucellosis (agent AA) Caprine brucellosis (agent AM) Agent US was in advanced development by the end of World ...
S. N. Stuart; Richard J. Adams (1990). Biodiversity in Sub-Saharan Africa and its Islands: Conservation, Management and ... French troops occupied the fort despite protests from the British Agent in Aden, Major Frederick Mercer Hunter, who dispatched ... Long-horned humpless cattle bones have likewise been discovered at Asa Koma, suggesting that domesticated cattle were present ... Density. 37.2/km2 (96.3/sq mi) (168th). GDP (PPP). 2018 estimate. ...
... the bones show osteosclerosis, increasing their density to provide ballast.[25] It has a reptilian gait, with the legs on the ... The Biodiversity Conservation Branch at the Department of Primary Industries and Water are collaborating with NRM north and ... is a secret agent. The choice of a platypus was inspired by media underuse, as well as to exploit the animal's striking ... However, the external opening of the ear still lies at the base of the jaw.[15] The platypus has extra bones in the shoulder ...
Bone, both human and animal, was also sculpted; human bones may have been trophies, or relics of ancestors.[191] The Maya ... The agents of the Catholic Church wrote detailed accounts of the Maya, in support of their efforts at evangelization, and ... The calculated density of market stalls at Chunchucmil strongly suggests that a thriving market economy already existed in the ... Miles, Susanna W. (1952). "An Analysis of the Modern Middle American Calendars: A Study in Conservation". In Sol Tax. ...
It is due to the scanner being unable to differentiate between a small amount of high-density material (e.g., bone) and a ... The contrast agent may induce contrast-induced nephropathy.[13] This occurs in 2 to 7% of people who receive these agents, with ... Payne, Emma Marie (2012). "Imaging Techniques in Conservation". Journal of Conservation and Museum Studies. Ubiquity Press. 10 ... The old radiocontrast agents caused anaphylaxis in 1% of cases while the newer, lower-osmolar agents cause reactions in 0.01- ...
... "induces bone formation and increases bone mineral density reducing the risk for osteoporosis and other bone disorders" pursuant ... Women who have undergone hysterectomy with ovary conservation go through menopause on average 3.7 years earlier than the ... Bevers TB (September 2007). "The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal ... EFSA Femarelle® and bone mineral density Archived 30 January 2012 at the Wayback Machine Scientific substantiation of a health ...
After initial reports that warfarin could reduce bone mineral density, several studies have demonstrated a link between ... V. Identification and synthesis of the hemorrhagic agent". J Biol Chem. 138 (2): 513-27. Archived from the original on 27 June ... New Zealand Department of Conservation. pp. 41-74. ISBN 978-0-478-22035-3. . Archived (PDF) from the original on 17 October ... There is a reversal agent available for dabigatran (idarucizumab)[24] but not for apixaban, edoxaban and rivaroxaban.[25] ...
... or in applications where its density is an asset. The plutonium can be used in the manufacture of mixed oxide fuel (MOX) for ... as extraction agents. The Purex process produces uranium, plutonium and fission products as separated chemical output streams. ... cancer of the blood or bone) and non-Hodgkin's lymphoma (NHL, a blood cancer) near two other nuclear installations including ... Energy use and conservation in the United Kingdom. *List of nuclear accidents ...
"Minerva Stone Conservation. Retrieved 22 September 2015.. *^ Klingelhöfer, G.; Morris, R. V.; Souza, P. A.; Rodionov, D.; ... At the bone marrow, transferrin is reduced from Fe3+ and Fe2+ and stored as ferritin to be incorporated into hemoglobin.[136] ... Iron(III) chloride finds use in water purification and sewage treatment, in the dyeing of cloth, as a coloring agent in paints ... Density (near r.t.). 7.874 g/cm3. when liquid (at m.p.). 6.98 g/cm3 ...
The high amount of calcium (Z = 20) in bones, together with their high density, is what makes them show up so clearly on ... A second image is then taken of the same region after an iodinated contrast agent has been injected into the blood vessels ... The transferred energy can be directly obtained from the scattering angle from the conservation of energy and momentum. ... Kevles, Bettyann Holtzmann (1996). Naked to the Bone Medical Imaging in the Twentieth Century. Camden, NJ: Rutgers University ...
Sathyakumar in Asiatic Black Bear Conservation Action Plan, chapter 10 of Bears: Status Survey and Conservation Action Plan ... However, the jaws of bears are controlled by large muscles that are capable of crushing bones, which gives access to the ... probably due in part to the density of population and competition for food sources.[33] One specimen, known as the sloth bear ... contamination from the environment is highly likely and means there is risk for tetanus and other external microbial agents. ...
... the bones show osteosclerosis, increasing their density to provide ballast.[27] It has a reptilian gait, with the legs on the ... "A national assessment of the conservation status of the platypus". Australian Conservation Foundation. Archived from the ... is a secret agent. The choice of a platypus was inspired by media underuse, as well as to exploit the animal's striking ... "Biological Conservation. 242: 108399. doi:10.1016/j.biocon.2019.108399. ISSN 0006-3207. Archived from the original on 31 ...
"Aquatic Conservation: Marine and Freshwater Ecosystems. Retrieved January 27, 2019.. CS1 maint: Uses authors parameter (link). ... Donald G. Reid, Stephen M. Herrero and Thomas E. Code, "River Otters as Agents of Water Loss from Beaver Ponds," Journal of ... Thurber, J. M.; Peterson, R. O. (1993). "Effects of Population Density and Pack Size on the Foraging Ecology of Gray Wolves". ... North American beavers have shorter nasal bones than their European relatives, with the widest point being at the middle of the ...
The ear and the muzzle contain a bone shape that is exclusive to cetaceans with a high density, resembling porcelain. This ... Whale and Dolphin Conservation Society. ISBN 978-0-646-47224-9. . Retrieved 5 September 2015.. ... Mysticeti have exceptionally thin, wide basilar membranes in their cochleae without stiffening agents, making their ears ... For this reason, the usual terrestrial compact bones, which are finely woven cancellous bone, are replaced with lighter and ...
The cause of death in the 2006 homicide of Alexander Litvinenko, a Russian KGB agent who had defected to the British MI6 ... Density (near r.t.). alpha: 9.196 g/cm3 beta: 9.398 g/cm3 ... Subcommittee on Energy Conservation and Power, published by U.S ... Medical tests indicated no harm, but the tests did not include bone marrow. Sadeh died from cancer. One of his students died of ... Internal Radioactive Contamination - Development of Decorporation Agents" (PDF). US Food and Drug Administration. Retrieved ...
... is most commonly used as an anti-corrosion agent,[104] and galvanization (coating of iron or steel) is the most familiar ... Most zinc is in the brain, muscle, bones, kidney, and liver, with the highest concentrations in the prostate and parts of the ... Meylan, Gregoire (2016). "The anthropogenic cycle of zinc: Status quo and perspectives". Resources, Conservation and Recycling ... Density (near r.t.). 7.14 g/cm3. when liquid (at m.p.). 6.57 g/cm3 ...
"Katanda Bone Harpoon Point , The Smithsonian Institution's Human Origins Program". Humanorigins.si.ed. Archived from the ... Gorillas, chimpanzees, and bonobos are all classified as endangered by the World Conservation Union, as well as the okapi, ... drying agents for paints and inks; ground coats for porcelain enamels; decolourisers for ceramics and glass; and pigments for ... Density. 34.83/km2 (90.2/sq mi). GDP (PPP). 2017 estimate. • Total ...
The population density is 308 km−2 (797.6/sq mi), lower than other Indian states. As per the census of 2011, the state has a ... In the early 1980s, palaeontologists found dinosaur bones and fossils of at least 13 species Balasinor in Kheda District.[176] ... Ebrahim, Alnoor (2000). "Agricultural cooperatives in Gujarat, India: Agents of equity or differentiation?". Development in ... "A conservation success story in the otherwise dire megafauna extinction crisis: The Asiatic lion (Panthera leo persica) of Gir ...
A bone marrow smear from a case of erythroleukemia. The large cell in the top center is an abnormal erythroblast: it is ... Epidermal nerve fiber density testing (ENFD) is a more recently developed neuropathology test in which a punch skin biopsy is ... With the new understanding of causative agents, physicians began to compare the characteristics of one germ's symptoms as they ... The hematopathologist reviews biopsies of lymph nodes, bone marrows and other tissues involved by an infiltrate of cells of the ...
The use of GE soy was also associated with greater conservation tillage, indirectly leading to better soil conservation, as ... van Die, MD; Bone, KM; Williams, SG; Pirotta, MV (2014). "Soy and soy isoflavones in prostate cancer: a systematic review and ... Soybeans contain phytic acid, which may act as a chelating agent and inhibit mineral absorption, especially for diets already ... and produce high-density linkage maps.[122] An SNP array was developed by Song et al 2013 and has been used for research and ...
In humans, copper is found mainly in the liver, muscle, and bone.[7] The adult body contains between 1.4 and 2.1 mg of copper ... Grieken, Rene van; Janssens, Koen (2005). Cultural Heritage Conservation and Environmental Impact Assessment by Non-Destructive ... Copper compounds are used as bacteriostatic agents, fungicides, and wood preservatives. Copper is essential to all living ... The maximum permissible current density of copper in open air is approximately 3.1×106 A/m2 of cross-sectional area, above ...
Agriculture, Fisheries and Conservation Department, "Penalty for Cruelty to Animals," Prevention of Cruelty to Animals (Chapter ... In Massachusetts and New York, agents of humane societies and associations may be appointed as special officers to enforce ... Farm animals are generally produced in large, industrial facilities that house thousands of animals at high densities; these ... the rag-and-bone man).[168][169] As Nigel Rothfels notes, the prohibition against dogs pulling carts in or near London caused ...
The Sindh Wildlife Conservation Building, located in Saddar, served as a Freemasonic Lodge until it was taken over by the ... The city's colonial-era core has traditionally a high density of small businesses. Karachi's downtown is centered on I. I. ... In 1995, Ziauddin Hospital was the site of Pakistan's first bone marrow transplant. Karachi municipal authorities in October ... though the modern community dates from the mid 19th century when they served as military contractors and commissariat agents to ...
"Bone Density Conservation Agents" by people in this website by year, and whether "Bone Density Conservation Agents" was a major ... Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE ... "Bone Density Conservation Agents" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH ( ... Below are the most recent publications written about "Bone Density Conservation Agents" by people in Profiles. ...
Bone Density Conservation Agents/therapeutic use*. *Drug Prescriptions/statistics & numerical data. *Drug Utilization/ ... Bone Density Conservation Agents. Grant support. *MR/K006665/1/Medical Research Council/United Kingdom ...
Bone Density Conservation Agents. Physiological Effects of Drugs. To Top. *For Patients and Families ... Proportion of subjects with change in bone mineral density [ Time Frame: 1 year ]. baseline and each post-treatment point ... Clonal bone marrow plasma cells , 60%. *An involved serum free light chain (kappa or Lambda) , 100mg/L with the ratio of the ... B: Absence of lytic bone lesions per IMWG recommendations:. One of either PET-CT, low-dose whole-body CT (LDWBCT) or MRI of the ...
Antineoplastic Agents, Hormonal. Selective Estrogen Receptor Modulators. Estrogen Receptor Modulators. Bone Density ... Patient must have either measurable disease or If no measurable disease is present, then at least one predominantly lytic bone ... Antineoplastic Agents. Aromatase Inhibitors. Steroid Synthesis Inhibitors. Enzyme Inhibitors. Molecular Mechanisms of ... Patient is currently using other antineoplastic agents. *Patient is pregnant or nursing or physiologically capable of becoming ...
Bone Density Conservation Agents. To Top. *For Patients and Families. *For Researchers ...
Bone Density Conservation Agents. To Top. *For Patients and Families. *For Researchers ...
PURPOSE: Bisphosphonates are commonly used for the treatment of osteoporosis and bone metastases caused by breast cancer and ... Bone Density Conservation Agents. *Bone Density Conservation Agents: therapeutic use. *Bone Neoplasms ... PURPOSE: Bisphosphonates are commonly used for the treatment of osteoporosis and bone metastases caused by breast cancer and ...
Bone Density Conservation Agents. Calcium-Regulating Hormones and Agents. To Top. *For Patients and Families ...
Bone Density Conservation Agents. *. Diphosphonates. Disclaimer: Information presented in this database is not meant as a ...
Bone Density Conservation Agents. *Calcium-Regulating Hormones and Agents. *Cholecalciferol, antagonists & inhibitors ... and bone metabolism [A223, L5689, L1782, L5771, F4027, F4042, F4048]. However, studies are also ongoing to determine whether or ... which makes vitamin D3 the preferred agent for medical use [L5689]. Appropriate levels of vitamin D must be upheld in the body ...
bone density conservation agent An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. ... calcitriol (CHEBI:17823) has role bone density conservation agent (CHEBI:50646) calcitriol (CHEBI:17823) has role calcium ... Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis. ... Agents that increase calcium influx into calcium channels of excitable tissues.. human metabolite Any mammalian metabolite ...
Bone Density Conservation Agents / administration & dosage* * Bone Density Conservation Agents / adverse effects ...
Antineoplastic Agents / pharmacology* * Apoptosis / drug effects * Bone Density Conservation Agents / pharmacology* * Caspase 1 ... Bisphosphonates (BPs) are a class of molecules which is effective in malignant bone diseases. The aim of the present study was ...
... and trabecular bone score (TBS) in hypoparathyroidism over a 2-yea... ... Bone Density Conservation Agents. Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. ... Lumbar Spine Bone Mineral Apparent Density in Children: Results from the Bone Mineral Density in Childhood Study. ... Bone Mineral Density in Pediatric Epilepsy. What are the effects of the currently used AEDs on bone mineralization in children ...
... clinicaltrials.gov Bone density was found to be impaired among lage babies and infants of diabetic mothers as found in small ... Bone Density Conservation Agents. Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. ... on bone mineral density and bone metabolism p.... Comparison of bone turnover markers in peripheral blood and bone marrow ... It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS. ...
Bone Density Conservation Agents/*administration & dosage/economics * Bone Density/physiology * Bone Diseases, Metabolic/ ... of bone turnover markers has the potential to identify a subset of post-menopausal women without osteoporosis by bone density ... Over half of all fractures among post-menopausal women occur in those who do not have osteoporosis by bone density criteria. ... level of a bone turnover marker. RESULTS: For women with high bone turnover, the cost per QALY gained with alendronate compared ...
0/Bone Density Conservation Agents; 0/Calcium, Dietary From MEDLINE®/PubMed®, a database of the U.S. National Library of ... Bone Density Conservation Agents / administration & dosage*. Calcium, Dietary / administration & dosage*. Cross-Sectional ... Previous Document: Cocoa flavanol-enriched snack bars containing phytosterols effectively lower total and low-density l.... ...
Bone Density / drug effects, physiology. Bone Density Conservation Agents / administration & dosage*. Diphosphonates / ... 0/Biological Markers; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Peptide Fragments; 0/Procollagen; 0/procollagen ... 14987325 - Transdermal hormone replacement therapy improves vertebral bone density in primary bili.... 15235345 - Effectiveness ... and bone mineral density (BMD). Fifty-two patients had been treated for at least 12 months, 38 with prior bisphosphonate ...
0 (Adaptor Proteins, Signal Transducing); 0 (Biomarkers); 0 (Bone Density Conservation Agents); 0 (Proteins); 0 (SQSTM1 protein ... In 1982, Prusiner investigated the infectious fraction of scrapie-infected brain homogenate, defined the infectious agent as ... The infectious agent was supposed to be a novel virus, so TSE was classified into slow virus infection. ...
0 (Bone Density Conservation Agents); 0 (Collagen Type I); 0 (Drug Combinations); 0 (Estrogens); 0 (Isoflavones); 0 (Peptides ... Buzz density was highly correlated with visual estimates of bumble bee density (r = 0.97), indicating that acoustic signals are ... RCE significantly attenuated bone mineral density (BMD) loss at the L2-L4 lumbar spine vertebra ( < 0.05), femoral neck ( < ... Buzz density predicted seed set in two alpine forbs when bumble bees were permitted access to the flowers, but not when they ...
Bone Density Conservation Agents. 2. 2009. 718. 0.470. Why? Sex Characteristics. 2. 2013. 2331. 0.460. Why? ...
... a creative approach to precisely estimate the risk of hip fracture by exploring the relationship between hip fracture and bone ... Keywords: Bone Density Conservation Agents, Geography, Medical, Hip Fractures, Osteoporosis. Full Text Order reprints Export ... Ex Vivo Evaluation of Hip Fracture Risk by Proximal Femur Geometry and Bone Mineral Density in Elderly Chinese Women. Xiao- ... to precisely estimate the risk of hip fracture by exploring the relationship between hip fracture and bone mineral density (BMD ...
Bone Density; Bone Density Conservation Agents; Denosumab; Double-Blind Method; Female; Fractures, Bone; Humans; Middle Aged; ... Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral ... Dual-energy X-ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture risk in untreated patients. ... 19 more authors) (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for ...
Bone Density Conservation Agents. 6. 3. Monoaminergic. 6. 3. P38 Mitogen-Activated Protein Kinase Modulator. 6. 5. ...
Bone Density Conservation Agents. 20. calcitonin. Interventional clinical trials:. #. Name. Status. NCT ID. Phase. Drugs. ... Affiliated tissues include lung, liver and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and ... The drugs Fibrinolytic Agents and Plasminogen have been mentioned in the context of this disorder. ...
Bone Density Conservation Agents. Not Applicable. 41. Vitamin D2. Nutraceutical. Not Applicable. ... Affiliated tissues include t cells, skin and bone, and related phenotype is neoplasm. ...
Bone Density Conservation Agents/adverse effects/*therapeutic use. Diphosphonates/therapeutic use. Female ... The accuracy of bone measurement tests to identify osteoporosis varied (area under the curve [AUC], 0.32-0.89). The pooled ... The accuracy of bone measurement tests or clinical risk assessments for identifying osteoporosis or predicting fractures varied ... bone measurement tests or clinical risk assessments, pharmacologic treatment. Data Extraction and Synthesis: Dual, independent ...
en] Bone Density/drug effects ; Bone Density Conservation Agents/therapeutic use ; Clinical Trials as Topic ; Drug Approval/ ... Recommendations for the registration of agents.pdf. No commentary. Publisher postprint. 89.46 kB. Request copy. ... Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update ... Reference : Recommendations for the registration of agents for prevention and treatment of glucoc.... ...
It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS. ... A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone ...
Bone Density Conservation Agents - Therapeutic Use. en_US. dc.subject.mesh. Diphosphonates - Adverse Effects - Therapeutic Use ... The primary endpoint was percentage change from baseline in lumbar spine bone mineral density. Drug efficacy was assessed on a ... The primary endpoint was percentage change from baseline in lumbar spine bone mineral density. Drug efficacy was assessed on a ... Findings: Zoledronic acid was non-inferior and superior to risedronate for increase of lumbar spine bone mineral density in ...
  • Technetium complexes of diphosphonates have been used successfully as bone scanning agents. (bvsalud.org)
  • An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. (ebi.ac.uk)
  • The continuous turnover of bone matrix and mineral that involves first, an increase in resorption (osteoclastic activity) and later, reactive bone formation (osteoblastic activity). (bioportfolio.com)
  • The bisphosphonates, widely used in the treatment of osteoporosis, act by inhibiting bone resorption. (zfin.org)
  • Additionally, the loss of connectivity in trabecular bone, and cortical bone thinning and loss of porosity are affected by an imbalance between bone formation and resorption. (peerj.com)
  • They inhibit ectopic calcification and slow down bone resorption and bone turnover. (bvsalud.org)
  • It inhibits ectopic calcification and slows down bone resorption and bone turnover. (bvsalud.org)
  • High serum homocysteine (HCY) and indirectly deficiency of folate and/or vitamin B(12) stimulate bone resorption and adversely affect collagen cross-linking. (springernature.com)
  • Bone resorption inhibitor in osteoporosis in postmenopausal women. (zentherapycenter.com)
  • The mechanism of action of pamidronate is inhibition of bone resorption. (drugbank.ca)
  • In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. (drugbank.ca)
  • Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. (illumina.com)
  • Multiple studies have shown that dietary intake of phytoestrogens derived from soy, lignans, or red clover reduces the risk of osteoporosis in postmenopausal women by inhibiting bone resorption, stimulating bone formation, preventing bone loss, and increasing bone mineral content. (grainbininc.com)
  • Because of their bone-selective pharmacokinetics, nitrogen-containing bisphosphonates (N-BPs), currently used as clinical inhibitors of bone-resorption diseases, target osteoclast farnesyl pyrophosphate synthase (FPPS) and inhibit protein prenylation. (ox.ac.uk)
  • OSTEOPOROSIS is permanent, includes reduction of total bone mass, and is associated with increased rate of fractures. (bioportfolio.com)
  • Rare autosomal recessive syndrome characterized by delayed closing of CRANIAL SUTURES, short stature, ACRO-OSTEOLYSIS of distal phalanges, dental and MAXILLOFACIAL ABNORMALITIES and an increase in bone density that results in frequent BONE FRACTURES. (bioportfolio.com)
  • INTRODUCTION AND HYPOTHESIS: Over half of all fractures among post-menopausal women occur in those who do not have osteoporosis by bone density criteria. (healthpartners.com)
  • If bisphosphonates therapy also reduced the risk of non-vertebral fractures by 20% among osteopenic women with high bone turnover, then the costs per QALY gained were $34,000 and $50,000 for women age 70 with high bone turnover and T-scores of -2.0 and -1.5, respectively. (healthpartners.com)
  • Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. (whiterose.ac.uk)
  • The accuracy of bone measurement tests or clinical risk assessments for identifying osteoporosis or predicting fractures varied from very poor to good. (pogoe.org)
  • Concurrent oral bisphosphonates increase bone mineral density and reduce frequency of vertebral fractures, but are associated with poor compliance and adherence. (hku.hk)
  • Combining whole-exome sequencing and filtering for homozygous stretches of identified variants, we found a homozygous causative BMP1 mutation, c.34G>C, in a consanguineous family affected by increased bone mineral density and multiple recurrent fractures. (zfin.org)
  • Women have twice the risk of getting fractures as men, making postmenopausal osteoporosis, which results from estrogen deficiency and leads to an increase in bone turnover, one of the most important types of primary osteoporosis. (peerj.com)
  • This can slow bone loss and may help prevent bone fractures. (zentherapycenter.com)
  • It has been theorized that phytoestrogens, such as isoflavonoids found in soy and red clover, may increase bone mineral density in postmenopausal women and reduce the risk of fractures. (grainbininc.com)
  • Appropriate levels of vitamin D must be upheld in the body in order to maintain calcium and phosphorus levels in a healthy physiologic range to sustain a variety of metabolic functions, transcription regulation, and bone metabolism [A223, L5689, L1782, L5771, F4027, F4042, F4048]. (rcsb.org)
  • We compared the effect of denosumab (60 mg every 6 months for 12 months) on bone mineral density and bone metabolism p. (bioportfolio.com)
  • Demographic and clinical data and genotyping of 10 single nucleotide polymorphisms (SNPs) from seven candidate genes associated with drug or bone metabolism were determined. (cdc.gov)
  • Alfacalcidol is an active metabolite of Vitamin D, which performs important functions in regulation of the calcium balance and the bone metabolism. (lifepharmaceuticalcompany.com)
  • Clinical Reviews in Bone and Mineral Metabolism. (elsevier.com)
  • This study was performed to determine reference intervals (RIs) for 2 bone turnover markers, serum C-terminal telopeptide of type I collagen (CTX) and osteocalcin, in Korean women.METHODS: A total of 461 Korean women (287 premenopausal and 174 postmenopausal) without any disease or drug history affecting bone metabolism was included. (bvsalud.org)
  • Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. (nih.gov)
  • Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study. (arctichealth.org)
  • RESULTS: For women with high bone turnover, the cost per QALY gained with alendronate compared to no drug therapy among women aged 70 years with T-scores of -2.0 or -1.5 were $58,000 and $80,000 (U.S. 2004 dollars), respectively. (healthpartners.com)
  • Q In postmenopausal women with low bone mineral density (BMD) who had been receiving daily alendronate for a mean of 5 years, what is the effect of continuing alendronate treatment for 5 years compared with discontinuing it? (bmj.com)
  • In this multicenter, randomized, open-label, 2-year, crossover study, 250 postmenopausal women with low bone mineral density received denosumab or alendronate for 12 months, then the other treatment for 12 months. (arctichealth.org)
  • Most treatments for skeletal metastases target bone-destroying osteoclasts and are palliative. (iupui.edu)
  • PURPOSE: Bisphosphonates are commonly used for the treatment of osteoporosis and bone metastases caused by breast cancer and were recently reported to be associated with a reduced risk of breast cancer, possibly acting through the mevalonate pathway, but their association with risk of other cancers is unknown. (mendeley.com)
  • Bisphosphonates (BPs) are a class of molecules which is effective in malignant bone diseases. (nih.gov)
  • Objective: The objective of the study was to compare the effect of transitioning from oral bisphosphonates to denosumab or ZOL on bone mineral density (BMD) and bone turnover. (uliege.be)
  • Conclusions: In postmenopausal women with osteoporosis previously treated with oral bisphosphonates, denosumab was associated with greaterBMDincreases at all measured skeletal sites and greater inhibition of bone remodeling compared with ZOL. (uliege.be)
  • Calcium and vitamin D supplementation, thiazide diuretics, and antiresorptive agents, such as gonadal hormone replacement, calcitonin, and bisphosphonates are available to prevent and reverse glucocorticoid-induced bone loss. (elsevier.com)
  • Bone remodeling takes place in the bone marrow environment. (bioportfolio.com)
  • A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone remodeling. (bioportfolio.com)
  • Agents that increase calcium influx into calcium channels of excitable tissues. (ebi.ac.uk)
  • Bone turnover markers did not decrease.Calcium supplementation had no effect on serum PTH and bone turnover.Daily vitamin D was more effective than weekly, and monthly administration was the least effective. (nih.gov)
  • Calcium supplementation had no effect on serum PTH and bone turnover. (nih.gov)
  • Pamidronate adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. (drugbank.ca)
  • Measurement of the amount of calcium in bone. (thefreedictionary.com)
  • Osteoporosis and diseases of bone loss are a major public health problem for the present and the future since longevity and prevalence of the disease are increasing in all parts of the world. (zfin.org)
  • Leuven University Centre for Metabolic Bone Diseases and Division of Geriatric Medicine, University of Leuven, Leuven, Belgium. (unboundmedicine.com)
  • We also characterize a zebrafish bone mutant harboring lesions in bmp1a , demonstrating conservation of BMP1 function in osteogenesis across species. (zfin.org)
  • We thus define the molecular and cellular bases of BMP1-dependent osteogenesis and show the importance of this protein for bone formation and stability. (zfin.org)
  • It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. (t3db.ca)
  • and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma. (drugbank.ca)
  • Life expectancy from first diagnosis of breast cancer bone metastases is several years, during which time skeletal-related events - including pain, fracture, hypercalcemia, and spinal cord compression - significantly degrade quality of life. (iupui.edu)
  • Recent results from the Breast cancer trials of Oral Everolimus-2 trial suggest that agents such as the mammalian target of rapamycin inhibitor everolimus may have efficacy against breast cancer bone metastases in part via stimulating osteoblasts as well as by inhibiting tumor growth. (iupui.edu)
  • This review discusses the future role of bone-anabolic agents for the specific treatment of osteolytic breast cancer metastases. (iupui.edu)
  • Stimulation of osteoblast activity inhibits multiple myeloma growth - a strategy that might decrease breast cancer burden in osteolytic bone metastases. (iupui.edu)
  • Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis. (bioportfolio.com)
  • Comparison of bone turnover markers in peripheral blood and bone marrow aspirate. (bioportfolio.com)
  • We investigated if levels of bone turnover markers (BTMs) differ between bone marrow and peripheral blood, if the bone marrow is an independ. (bioportfolio.com)
  • CONCLUSION: Measurement of bone turnover markers has the potential to identify a subset of post-menopausal women without osteoporosis by bone density criteria for whom bisphosphonate therapy to prevent fracture is cost-effective. (healthpartners.com)
  • serum levels of 25-hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH) and bone turnover markers. (nih.gov)
  • Bone turnover markers did not decrease. (nih.gov)
  • However, there are limited data regarding the long-term effect of once-weekly teriparatide therapy on bone mineral density (BMD), bone turnover markers (BTMs), and anabolic bone window. (henryford.com)
  • Main Outcome Measures: Changes in BMD and bone turnover markers were measured. (uliege.be)
  • Short-term changes in bone turnover markers and bone mineral density r" by D C. Bauer, P Garnero et al. (jax.org)
  • Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. (jax.org)
  • CONTEXT: Treatment of osteoporotic women with PTH increases biochemical markers of bone turnover, increases axial bone mineral density (BMD), and reduces fracture risk. (jax.org)
  • MAIN OUTCOME MEASURE: Bone turnover markers were measured in fasting blood samples collected before therapy and after 1 and 3 months. (jax.org)
  • Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. (bioportfolio.com)
  • en] Context: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. (uliege.be)
  • It has a role as a human metabolite, an anti-inflammatory agent, a neuroprotective agent, an apoptosis inhibitor, a cardioprotective agent and a bone density conservation agent. (aasraw.com)
  • Bone Density Conservation Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (uchicago.edu)
  • Dual-energy X-ray absorptiometry (DXA) is a cornerstone of pediatric bone health assessment, yet differences in height-for-age confound the interpretation of areal bone mineral density (aBMD) measures. (bioportfolio.com)
  • Bone mineral density (BMD) was measured at the 1st to 4th lumbar vertebra using dual energy X-ray absorptiometry. (bvsalud.org)
  • The bone mineral density of the lumbar spine and total hip was measured every 6 months with the use of dual-energy X-ray absorptiometry. (unboundmedicine.com)
  • OSTEOFORM, containing recombinant (rhPTH [1-34]), enhances bone mineral density and reduces risk for vertebral fracture. (bioportfolio.com)
  • Agents with both anti-tumor and bone-anabolic actions have been tested in the setting of multiple myeloma, a hematological malignancy that causes severe osteolytic bone loss and suppression of osteoblastic new bone formation. (iupui.edu)
  • Blood samples for HCY, folate, vitamin B(12), 25-hydroxyvitamin D (25-OH-D), total serum alkaline phosphatase (TSAP), bone-specific serum alkaline phosphatase (BSAP) and C-terminal cross-linking telopeptide of type I collagen (CTX) were obtained at baseline and 3, 6 and 12 months after ZOL infusion. (springernature.com)
  • Protease inhibitors (PI) have been associated with an acceleration of bone mineral density loss in HIV-infected individuals because of an enhanced osteoclast activity, although some contro. (bioportfolio.com)
  • Results: SEM images demonstrated that alveolar bone loss was reduced in the periodontitis mouse model after VD3 supplementation. (bvsalud.org)
  • The drugs Fibrinolytic Agents and Plasminogen have been mentioned in the context of this disorder. (malacards.org)
  • Background: Persistent use of glucocorticoid drugs is associated with bone loss and increased fracture risk. (hku.hk)
  • Bonviva is a drug from the pharmacological group of drugs, the action of which is aimed at the treatment of bone tissue. (zentherapycenter.com)
  • Premenopausal RIs for serum CTX and osteocalcin would be useful to monitor patients with low bone mass using osteoporosis drugs. (bvsalud.org)
  • Osteonecrosis of the jaw could occur after intake of bisphosphonate drugs, which are widely used to treat osteoporosis and bone metastasis of malignant tumors. (bvsalud.org)
  • It was hypothesized that the concurrent administration of chemotherapeutic agents could be eventually considered as a factor able to allow a faster worsening of the clinical manifestation through the exacerbation of soft tissue defects, due to chemotherapy drugs. (unipa.it)
  • Drugs with limited anti-tumor activity but which are anabolic for bone include intermittent parathyroid hormone and antibodies that neutralize the WNT inhibitors DKK1 and sclerostin, as well as the activin A blocker sotatercept and the osteoporosis drug strontium ranelate. (iupui.edu)
  • Prochaska M, Taylor E, Vaidya A, Curhan G. Low Bone Density and Bisphosphonate Use and the Risk of Kidney Stones. (uchicago.edu)
  • METHODS: Using a Markov model, we estimated the cost per quality adjusted life year (QALY) for five years of oral bisphosphonate compared to no drug therapy for osteopenic post-menopausal women aged 60 to 80 years with a high (top quartile) or low (bottom 3 quartiles) level of a bone turnover marker. (healthpartners.com)
  • 2.5 and high bone turnover and the cost of bisphosphonate treatment. (healthpartners.com)
  • Patients were divided into two groups depending on whether or not they had prior bisphosphonate exposure, and the response to teriparatide was compared using procollagen of type 1 N-terminal propeptide (P1NP) and bone mineral density (BMD). (biomedsearch.com)
  • Ibandronate is a bisphosphonate (bis FOS fo nayt) medicine that alters bone formation and breakdown in the body. (zentherapycenter.com)
  • Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. (zentherapycenter.com)
  • Vitamin D3 analogs and intermittent parathyroid hormone (PTH) result in dose-dependent increases in the formation of mineralized bone, whereas continuous exposure to PTH results in net bone loss. (zfin.org)
  • Teriparatide (a fragment of parathyroid hormone) is the only approved anabolic agent. (peerj.com)
  • Osteoblasts and their precursors support hematopoiesis in the bone marrow. (bioportfolio.com)
  • To facilitate the identification of novel anabolic therapies, the authors have developed a rapid, high-throughput in vivo screen using larval zebrafish (Danio rerio) in which they are able to identify agents with anabolic effects in the skeleton within a 6-day time period. (zfin.org)
  • Because this model is fast, economical, and genetically tractable, it provides a powerful adjunct to mammalian models for the identification of new anabolic bone agents and offers the potential for genetic elucidation of pathways important in osteoblastic activity. (zfin.org)
  • Anabolic bone window with weekly teriparatide therapy in post menopaus" by Vinaya Gopalaswamy, Deba Prasad Dhibar et al. (henryford.com)
  • CONCLUSION: Weekly teriparatide therapy (60 μg) appears to be as effective as daily teriparatide for the treatment of PMO by extending the anabolic bone window. (henryford.com)
  • Treatment of fracture non-union in a young adult with combination anabolic and anti-resorptive bone therapy. (ox.ac.uk)
  • Proteasome inhibitors (bortezomib and carfilzomib) inhibit the growth of myeloma directly and are anabolic for bone. (iupui.edu)
  • Transforming growth factor-beta inhibitors have little tumor antiproliferative activity but block breast cancer production of osteolytic factors and are also anabolic for bone. (iupui.edu)
  • This review provides an overview of agents with bone-anabolic properties, which may have utility in the treatment of breast cancer metastatic to the skeleton. (iupui.edu)
  • Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients? (unipa.it)
  • To evaluate the relationship between bone mineral density (BMD) and magnetic susceptibility, and between proton density fat fraction and susceptibility, in inflamed trabecular bone. (bioportfolio.com)
  • Bone morphogenetic protein 1 (BMP1) is an astacin metalloprotease with important cellular functions and diverse substrates, including extracellular-matrix proteins and antagonists of some TGFβ superfamily members. (zfin.org)
  • Osteoporosis, described as the microstructural degeneration of bone tissue and low bone mass, is a systemic skeletal disease causing incremental bone fragility and sensitivity to fracture. (peerj.com)
  • n test that determines bone density according to the radiation absorption rate of the skeletal structure being tested. (thefreedictionary.com)
  • The aim of this study was the evaluation of serum levels of HCY, folate and vitamin B(12) in patients with Paget's disease of bone (PDB) and the effect of zoledronic acid (ZOL) on their serum levels. (springernature.com)
  • INTERPRETATION: A single 5 mg intravenous infusion of zoledronic acid is non-inferior, possibly more effective, and more acceptable to patients than is 5 mg of oral risedronate daily for prevention and treatment of bone loss that is associated with glucocorticoid use. (elsevier.com)
  • These data show that early application of zoledronic acid 5 mg/year was well stimulated and tolerated for bone mass in newly diagnosed east china subjects with osteoporosis in a 24-month treatment. (unboundmedicine.com)
  • Lumbar Spine Bone Mineral Apparent Density in Children: Results from the Bone Mineral Density in Childhood Study. (bioportfolio.com)
  • The primary endpoint was percentage change from baseline in lumbar spine bone mineral density. (hku.hk)
  • Journal of Bone and Mineral Research (JBMR), 27 (3). (whiterose.ac.uk)
  • Khosla, S 2012, ' Odanacatib: Location and timing are everything ', Journal of Bone and Mineral Research , vol. 27, no. 3, pp. 506-508. (elsevier.com)
  • Afterwards, we examined the alveolar bone using scanning electron microscopy (SEM) and detected the gingival epithelial protein using western blot analysis and immunohistochemical staining. (bvsalud.org)
  • The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry. (bioportfolio.com)
  • What are the effects of the currently used AEDs on bone mineralization in children and adolescents between the ages of 8 to 18? (bioportfolio.com)
  • The Effects of Dispersal and Predator Density on Prey Survival in an Insect-Red Clover Metacommunity. (bireme.br)
  • Heteroptera: Nabidae), to determine the effects of conspecific and predator density and varying the time available to dispersal among mesocosms on predation rates, dispersal rates, and leafhopper survival. (bireme.br)
  • These agents may have additive effects in preventing bone loss when used in combination. (elsevier.com)